Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

452.16 +6.96 (+1.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
62 63 Next >
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities... 
Via Benzinga
These 2 Incredible Growth Stocks Are Set to Soar This Summer and Beyond
It's always a good time to invest cash in quality businesses. 
Via The Motley Fool
3 Fantastic Growth Stocks to Buy in August
These stocks should keep up their winning ways. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotech Stocks to Buy on the Dip: August 2024
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning. 
Via InvestorPlace
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
Via Benzinga
Vertex Slumps On Light Second-Quarter Despite Hiked 2024 Outlook
The company's sales came in a hair light with losses wider than expected. 
Via Investor's Business Daily
14 Analysts Assess Vertex Pharmaceuticals: What You Need To Know
Via Benzinga
Prediction: These 4 Future Technologies Will Be Millionaire-Makers -- and Here Are the Top Stocks to Buy Now to Profit From Them
These technologies could be game-changers. And they could make forward-thinking investors a lot of money. 
Via The Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in August
Both of these biotechs are highly innovative companies. 
Via The Motley Fool
The 3 Best Biotech Stocks to Buy in August 2024
These biotech stocks are leading the way with groundbreaking therapies and robust fundamentals offering superb upside ahead. 
Via InvestorPlace
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
From Vertex Pharmaceuticals
Via Business Wire
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Shares of the rare disease drugmaker are already up more than 40% over the past year. 
Via The Motley Fool
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
Great companies are found in every type of market landscape. 
Via The Motley Fool
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker
The biotech recently became a commercial-stage company. 
Via The Motley Fool
3 Unstoppable Stocks to Buy in August
It's not hard to envision how all three of these stocks can deliver exceptional growth. 
Via The Motley Fool
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
These two healthcare companies have far more upside potential than Johnson & Johnson. 
Via The Motley Fool
3 Biotech Stocks That Could Have Investors Grinning Soon
Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential. 
Via InvestorPlace
Magnificent 7 Lose Over $300B As Volatility Index Surges, Traders Question Fed's Timing: What's Driving Markets Friday?
Wall Street is experiencing a sharp decline on the last trading day of the week, with all indices in the red at noon in New York, as a cooler-than-expected July jobs report rattled risk sentiment and... 
Via Benzinga
Topics Economy
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Vertex Pharmaceuticals reported Q2 revenues of $2.65B, near the $2.66B estimate, with an adjusted EPS loss of $(12.83), missing the $4.14 consensus. The analyst expects strong growth in the pain... 
Via Benzinga
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
Vertex's first loss in years is a big nothingburger. 
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q2 2024 Earnings Call Transcript
VRTX earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Vertex Reports Second Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market... 
Via Benzinga
Got $500? 2 Compelling Growth Stocks to Buy and Hold Forever
These businesses are looking like increasingly attractive buys. 
Via The Motley Fool
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a... 
Via Benzinga
The Top 3 Biotech Stocks to Buy Now Summer 2024
These biotech stocks are well-positioned to generate high returns for investors due to their significant growth prospects. 
Via InvestorPlace
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.